Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).

TitleMetabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).
Publication TypeJournal Article
Year of Publication2007
AuthorsCust, AE, Kaaks, R, Friedenreich, C, Bonnet, F, Laville, M, Tjønneland, A, Olsen, A, Overvad, K, Jakobsen, MUhre, Chajès, V, Clavel-Chapelon, F, Boutron-Ruault, M-C, Linseisen, J, Lukanova, A, Boeing, H, Pischon, T, Trichopoulou, A, Christina, B, Trichopoulos, D, Palli, D, Berrino, F, Panico, S, Tumino, R, Sacerdote, C, Gram, ITorhild, Lund, iv, E, Quiros, JR, Travier, N, Martínez-García, C, Larrañaga, N, Chirlaque, M-D, Ardanaz, E, Berglund, G, Lundin, E, H Bueno-de-Mesquita, B, van Duijnhoven, FJB, Peeters, PHM, Bingham, S, Khaw, K-T, Allen, N, Key, T, Ferrari, P, Rinaldi, S, Slimani, N, Riboli, E
JournalEndocr Relat Cancer
Date Published2007 Sep
KeywordsAdenocarcinoma, Adult, Blood Glucose, Case-Control Studies, Endometrial Neoplasms, Europe, Female, Humans, Lipids, Lipoproteins, Metabolic Syndrome, Middle Aged, Nutritional Physiological Phenomena, Prospective Studies, Risk Factors

To clarify the role of metabolic factors in endometrial carcinogenesis, we conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), and examined the relation between prediagnostic plasma lipids, lipoproteins, and glucose, the metabolic syndrome (MetS; a cluster of metabolic factors) and endometrial cancer risk. Among pre- and postmenopausal women, 284 women developed endometrial cancer during follow-up. Using risk set sampling, 546 matched control subjects were selected. From conditional logistic regression models, high-density lipoprotein cholesterol (HDL-C) levels were inversely associated with risk body mass index (BMI)-adjusted relative risk (RR) for top versus bottom quartile 0.61 (95% confidence intervals (CI) 0.38-0.97), P(trend) = 0.02). Glucose levels were positively associated with risk (BMI-adjusted RR top versus bottom quartile 1.69 (95% CI 0.99-2.90), P(trend) = 0.03), which appeared stronger among postmenopausal women (BMI-adjusted RR top versus bottom tertile 2.61 (95% CI 1.46-4.66), P(trend) = 0.0006, P(heterogeneity) = 0.13) and never-users of exogenous hormones (P(heterogeneity) = 0.005 for oral contraceptive (OC) use and 0.05 for hormone replacement therapy-use). The associations of HDL-C and glucose with risk were no longer statistically significant after further adjustment for obesity-related hormones. Plasma total cholesterol, Low-density lipoprotein cholesterol (LDL-C), and triglycerides were not significantly related to overall risk. The presence of MetS was associated with risk (RR 2.12 (95% CI 1.51-2.97)), which increased with the number of MetS factors (P(trend) = 0.02). An increasing number of MetS factors other than waist circumference, however, was marginally significantly associated with risk only in women with waist circumference above the median (P(interaction) = 0.01). None of the associations differed significantly by fasting status. These findings suggest that metabolic abnormalities and obesity may act synergistically to increase endometrial cancer risk.

Alternate JournalEndocr. Relat. Cancer
Citation Key10.1677/ERC-07-0132
PubMed ID17914105
Grant ListG0401527 / / Medical Research Council / United Kingdom
/ / Wellcome Trust / United Kingdom